- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial primary completion date: Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer (clinicaltrials.gov) - Dec 4, 2015 P2, N=100, Active, not recruiting, Trial primary completion date: Dec 2018 --> Dec 2020 Trial primary completion date: Jul 2015 --> Dec 2015
- |||||||||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity (clinicaltrials.gov) - Dec 3, 2015 P4, N=500, Recruiting, Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Dec 2018 --> Dec 2020
- |||||||||| Cervidil (dinoprostone) / Ferring
Trial completion: CYTOPRO: Comparison Between 25 (clinicaltrials.gov) - Nov 30, 2015 P2, N=1700, Completed, Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment closed, Enrollment change, Metastases: Effectiveness and Safety of Firmagon (clinicaltrials.gov) - Oct 30, 2015 P=N/A, N=103, Active, not recruiting, Primary objectives could not be met due to critical missing information. Recruiting --> Active, not recruiting | N=200 --> 103
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: ProComD: Therapy Pathways in the Treatment of Hormone Na (clinicaltrials.gov) - Oct 22, 2015 P=N/A, N=1500, Recruiting, Initiation date: Sep 2015 --> Dec 2016 | Trial primary completion date: Dec 2016 --> Mar 2018 Trial primary completion date: Dec 2018 --> Mar 2020
- |||||||||| Lutrelef (gonadorelin acetate) / Ferring
Trial primary completion date: LutrePulse Hypogonadotropic Hypogonadism (clinicaltrials.gov) - Oct 22, 2015 P3, N=60, Recruiting, Trial primary completion date: Dec 2018 --> Mar 2020 Trial primary completion date: Apr 2016 --> Apr 2017
- |||||||||| Yervoy (ipilimumab) / BMS
Trial primary completion date: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Oct 22, 2015 P2, N=48, Active, not recruiting, Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Enrollment open: MEGASET HR: MENOPUR (clinicaltrials.gov) - Oct 22, 2015 P4, N=600, Recruiting, Trial primary completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Sep 25, 2015 P3, N=880, Completed, Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Firmagon (degarelix) / Astellas, Ferring, T+AiTM (testosterone/anastrozole) / Havah Therapeutics
Trial primary completion date: Impact of Estradiol Addback (clinicaltrials.gov) - Sep 24, 2015 P1, N=60, Recruiting, Trial primary completion date: Aug 2015 --> Feb 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
New P4 trial: MEGASET HR: MENOPUR (clinicaltrials.gov) - Sep 18, 2015 P4, N=600, Not yet recruiting,
|